GNRH1 and ovarian hyperstimulation syndrome: Elgindy et al. (16) conducted a RCT comparing IM vs. vaginal progesterone administration in patients with increased baseline OHSS risk that were triggered with either GnRH agonist or 5,000 IU of HCG.